JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
REVIEW
Add like
Add dislike
Add to saved papers

Paget disease of bone: therapeutic options.

Paget disease of bone is a disorder of unknown etiology involving disturbances in bone remodeling, typically leading to bone pain and other complications such as skeletal deformities, fractures, hearing loss, and neurologic complications. Bisphosphonates (BPs), both oral and intravenous, have improved Paget treatment by reducing and normalizing bone turnover, as measured by biochemical markers and by alleviating symptoms. Six BPs are currently approved by the US Food and Drug Administration (FDA) for the treatment of Paget disease, and each has unique characteristics, such as response rates and requirements for dosage and administration, relevant to clinical outcome. This review provides an overview of these agents-including oral drugs such as alendronate and risedronate, and the intravenous agent zoledronic acid-and briefly discusses other options for managing Paget disease and monitoring treatment efficacy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app